Parallax Volatility Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-49,279
Closed -$396K 1555
2025
Q1
$396K Buy
49,279
+9,647
+24% +$78.2K ﹤0.01% 1227
2024
Q4
$356K Sell
39,632
-33,540
-46% -$274K ﹤0.01% 1570
2024
Q3
$536K Sell
73,172
-6,718
-8% -$41.7K ﹤0.01% 1509
2024
Q2
$456K Sell
79,890
-7,825
-9% -$41.2K ﹤0.01% 1452
2024
Q1
$439K Sell
87,715
-47,674
-35% -$323K ﹤0.01% 1438
2023
Q4
$1.22M Sell
135,389
-28,858
-18% -$238K ﹤0.01% 1338
2023
Q3
$1.28M Buy
164,247
+13,295
+9% +$130K ﹤0.01% 1265
2023
Q2
$1.46M Buy
150,952
+8,503
+6% +$88.3K ﹤0.01% 1252
2023
Q1
$1.56M Sell
142,449
-107,730
-43% -$949K ﹤0.01% 1322
2022
Q4
$1.08M Buy
250,179
+3,616
+1% +$21K ﹤0.01% 1627
2022
Q3
$1.85M Buy
246,563
+46,082
+23% +$399K ﹤0.01% 1455
2022
Q2
$2.02M Sell
200,481
-1,927
-1% -$21.5K ﹤0.01% 1348
2022
Q1
$2.51M Buy
+202,408
New +$3.13M ﹤0.01% 1276
2017
Q4
Sell
-49,702
Closed -$312K 3943
2017
Q3
$312K Buy
49,702
+30,951
+165% +$195K ﹤0.01% 1362
2017
Q2
$115K Sell
18,751
-31,294
-63% -$211K ﹤0.01% 1604
2017
Q1
$367K Sell
50,045
-7,426
-13% -$34.3K ﹤0.01% 1651
2016
Q4
$121K Buy
+57,471
New +$185K ﹤0.01% 2112

Other funds holding AUPH

Parallax Volatility Advisers's AUPH Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 49,279 shares — an estimated $396K sold.

Parallax Volatility Advisers first reported a position in AUPH in Q4 2016 and held it in 17 quarters. The position peaked at $2.51M in Q1 2022. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 49,279 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $396K.
  • Parallax Volatility Advisers first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 17 quarters.
  • Parallax Volatility Advisers's Aurinia Pharmaceuticals position peaked at $2.51M in Q1 2022.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.